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Angiogenesis is an essential process in the progres-
sion of malignant tumors due to the fact that solid
tumors cannot grow beyond 1-2 mm in diameter with-
out neovascularization (1). Various growth factors have
proved to stimulate angiogenesis, including the fibrob-
last growth factor (FGF), the transforming growth fac-
tor alpha (TGFα), the plateled-derived growth factor
(PDGF) and the vascular endothelial growth factor
(VEGF) (2) which is the most potent angiogenic factor,
a glycoprotein with angiogenic, mitogenic, and vascu-
lar permeability enhancing activity in endothelial cells
(3). Moreover several studies have reported that the
potential of VEGF signal-pathway inhibitors as anti-
cancer agent in non-small cell lung cancer (NSCLC)
treatment disturbs growth and migration of the cancer
cells (4,5).
In 1991 Weidner et al. (6) showed that assessing
tumor microvessel density (MVD) could be useful in
evaluating the aggressiveness of breast carcinoma.
Since then similar observations have been found for
other types of malignancies including NSCLC. How-
ever, several studies have failed to show MVD as a sig-
nificant prognostic factor (7,8).
The CD34 is an endothelial antigen that has been
used to highlight the MVD as a direct marker of the
degree of neoangiogenesis; however, it can react with
not only "newly forming" vessels but also with normal
vessels just trapped within a tumor tissues (9)
In the present study we report the VEGF expression
and its relationship with MVD in two NSCLC lin-
eages: adenocarcinomas and epidermoid carcinomas
with low differentiation, using immunohistochemistry
with anti VEGF and anti CD34, in order to consider the
possibility of using the correlation between both anti-
bodies as a prognostic factor for patients’ survival.
Materials and Methods
Tumor
Tumor specimens from 72 patients with previously
untreated epidermoid lung carcinoma and adenocarci-
noma with low differentiation in stage I and II surgi-
cally treated at the Hospital Interzonal Especializado
de Agudos y Crónicos San Juan de Dios, La Plata, were
analyzed for VEGF expression and microvessel densi-
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Angiogenesis is an essential process in the progression of malignant tumors and the most potent angiogenic fac-
tor is the vascular endothelial growth factor (VEGF). On the other hand, the CD34 is an endothelial antigen that
has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoan-
giogenesis. In the present study we report the VEGF expression and its relationship with MVD, measured by
CD34, in two lineages of non-small cell lung cancer (NSCL): low differentiated adenocarcinomas and epider-
moid carcinomas, in order to consider the possibility of using the correlation between both antibodies as a prog-
nostic factor. Tumor sections were stained by immunohistochemistry for CD34 and VEGF. The results showed
that the mean value of VEGF for adenocarcinoma was significantly higher than the one for epidermoid carcino-
ma (p < 0.001). However, the mean of MVD did not show significant differences between both types of tumors.
The conventional factors taken into consideration (age over 60, sex, and presence of lymph nodes) was not sig-
nificantly related to the angiogenic factors examined. In conclusion, we could affirm that CD34 is a better prog-
nostic marker of neoangiogenesis in NSCLC, because both types of tumors have the same clinical prognosis, and
so we expected the same behaviour from both markers.
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ty. The histological classification of tumors was based
on the guidelines of the World Health Organization
(1981). The mean age of the patients was 56.5 years
(range 49-67), 59 male and 13 female.
Determination of VEGF and CD34 Expression
Desparaffinized and rehydrated sections were
microwaved for 10 min. in buffer citrate, PH 6.
Endogenous peroxidase was blocked for 20 min. The
primary antibody against VEGF-C1 (mouse mono-
clonal antibody; Santa Cruz Biotechnology, Califor-
nia,  USA 1:100 dilution) and a mouse monoclonal
antibody against CD34 protein (Santa Cruz, Biotech-
nology, California, USA 1:80 dilution) were incubat-
ed for 60 min. Bound primary antibody was detected
by Envision Systen (Dako) for 30 min. and the reac-
tion was developed using diaminobenzidine, and
counter staining with Mayer hematoxylin. The posi-
tive control was a section of lung tumor that had
shown  to have a high VEGF content previously, by
immunohistochemistry. VEGF staining was seen in
the tumor cell cytoplasm.
The expression of VEGF was assessed acording to
the percentage of immunoreactive cells in a total of
1000 neoplastic cells (quantitative analysis). There was
> 95% agreement between the two observers for the
VEGF evaluation. A final score was determined by
consensus after re-examination. MVD was assessed
using the criteria of Weidner et al. (6). The areas of
highest vascularization were identified as regions of
invasive carcinoma with the highest numbers of dis-
crete microvessels stained for CD34. Any brown
stained endothelial cell or endothelial cell cluster that
was clearly separated from adjacent microvessels,
tumor cells and other connective tissue elements was
considered a single, countable microvessel. Each count
was expressed as the highest number of microvessel
identified within a 0.3 mm2 fields at a magnification of
X 200. Ten fields of the most intense vascularization
(hotspot) were analyzed for each tumor. Two investiga-
tors performed all counts  simultaneously, both had to
agree on what constituted a single microvessel before a
vessel was included in the count.
Statistical Analysis
The statistical analysis of VEGF expression was
performed using Student Test, because the distribution
of samples was normal. The marked tumoral cells were
recorded by counting 50 areas, and the total nuclei
every 10 areas. The results were expressed as a per-
centage of marked cells. 
The CD34 expression was analyzed by Student Test
and was expressed as X ± SE of the total of marked
vessels in the selected areas for every tumor.
Results
Table I: summarizes all the clinical data about the
patients enrolled in this study.
Table II: shows the immunohistochemical expres-
sion of the angiogenic factors evaluated. High expres-
sion of VEGF was seen in 28 patients (82%) with ade-
nocarcinoma and in 9 (24%) with epidermoid carcino-
ma, and a high expression of MVD as assessed by
CD34, was seen in 18 patiens (53%) with adenocarci-
noma and in 22 (58%) with epidermoid carcinoma.   
Table III: shows the mean of immunohistochemical
parameters of angiogenic factors and the conventional
risk factors taken into account in this study, like age,
sex, and the presence of positive lymph nodes. In this
table we could also observe that VEGF expression in
adenocarcinoma was significantly higher than in epi-
dermoid carcinoma (p< 0.001), but the MDV measured
by CD34 expression did not show any significant dif-
ference between both tumor types.
At the end of our study two patients died, a high
expression of CD34 was observed in both, but only one
had a high expression of VEGF. Both of them, evi-
denced the presence of positive lymph nodes, and they
were smokers.   
Discussion 
Angiogenesis is a complex process that involves
endothelial cell migration, capillary bredding, neovas-
cular remodelling, in addition to endothelial cell pro-
liferation. The growth of solid tumors like those anal-
ized in this study, needs an adequate vascular network
for the supply of oxygen and nutrients, and in order to
remove waste products, although it has been estab-
lished that tumor cell proliferation decreases with
increasing distances from the blood vessels (10). 
Ushijima et al. (11) have demonstrated that high
MVD is associated with the  advancement of NSCLC,
and this was particularly evident in conjunction with
high VEGF expression. On the contrary, in our study
we found a higher VEGF-C expression in adenocarci-
nomas than in epidermoid lung carcinoma, even
though the microvessel density, marked with CD34
expression, did not show differences between tumors.
These observations are in agreement with Ghio P. et al.
(12) but not with Nakashima T. et al. who found that
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VEGF-C expression is one of the significant prognos-
tic factors in patients with squamous cell carcinomas
(13). Our results as for low differentiated lung carcino-
mas may be consistent with other studies (14,15) and
carcinoma of oesophagus (16), who found no correla-
tion of microvessel density with tumor cell prolifera-
tion.
Interestingly, VEGF-C expression is higher in ade-
nocarcinomas than in epidermoid carcinoma, while the
MVD and the positive presence of lymph nodes are
similar in both tumors´ lineages. This can be due to the
fact that the CD34 is more strictly related to the
metastatic process than to neoangiogenesis  itself. Yano
et al. have recently demonstrated a higher incidence of
VEGF and CD34 in Human NSCLC
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Table I - Study population features divided according to tumoral type
Conventional Total (n) Percentage (%)
risk factors Adeno Epid. Adeno Epid.
Sex
- Male 29 30 76.3 88.2
- Female 9 4 23.7 11.8
Smoker
- No 4 5 10.5 14.7
- Yes 34 29 89.5 85.3
Surgical procedures
- lobectomy 30 32 78.9 94.1
- pneumonectomy 8 2 21.1 5.9
Grading
- G1 10 4 26.3 11.8
- G2 28 30 73.7 88.2
Age
#55 5 2 13.2 5.9
56 to 65 26 27 68.4 79.4 
$65 7 5 18.4 14.7
(n): Number of patients
Adeno.: Adenocarcinoma
Epid.: Epidermpoid carcinoma 
Table II - Number of patients with NSCLC and their
inmunohistochemical parameters
VEGF CD34
Adeno Epid. Adeno Epid.
Strong 28/34 9/38 18/34 22/38
Low 6/34 29/38 16/34 16/38
Adeno.: Adenocarcinoma
Epid.: Epidermpoid carcinoma 
The values were expressed as number of patients /total number of patients.
Table III - Immunohistochemical parameters of angiogenic
factors and conventional risk factors
Adenocarcinoma Epidermoid p <
(n) 34 38
VEGF (x) 44 ± 6.1 1.8 ± 0.5 0.001
CD34 (x) 5.1 ± 1.2 6.3 ± 0.8 ns




Lymph nodes + 18 20
Lymph nodes - 16 18
P: probability
(n): number of patients
(x): mean ± SD
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distant metastases and shorter survival in patients with
high grade of MVD as assessed by CD34 (17).
All the patients were operated last year (2006), so
we can affirm that the survival was high, because only
two patients died, but we assume that more time will be
necessary to reach a real conclusion.
The main limitation of our study is the small sam-
ple size: we chose only  untreated patients with stages
I and II of both tumoral lineages with low differentia-
tion. Even though previous works assumed that VEGF
and CD34 are excellent markers of neoangiogenesis in
NSCLC (2-4,17-19), on the basis of our preliminary
results, we could affirm that CD34 is a better prognos-
tic marker of neoangiogenesis in NSCLC, because
both types of tumors have the same clinical prognosis,
and so we expected the same behaviour from both
markers.
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